Literature DB >> 22365663

Constitutive type I interferon modulates homeostatic balance through tonic signaling.

Daniel J Gough1, Nicole L Messina, Christopher J P Clarke, Ricky W Johnstone, David E Levy.   

Abstract

Interferons (IFNs) were discovered as cytokines induced during and protecting from viral infection. They have been documented to play essential roles in numerous physiological processes beyond antiviral and antimicrobial defense, including immunomodulation, cell cycle regulation, cell survival, and cell differentiation. Recent data have also uncovered a potentially darker side to IFN, including roles in inflammatory diseases, such as autoimmunity and diabetes. IFN can have effects in the absence of acute infection, highlighting a physiologic role for constitutive IFN. Type I IFNs are constitutively produced at vanishingly low quantities and yet exert profound effects, mediated in part through modulation of signaling intermediates required for responses to diverse cytokines. We review evidence for a yin-yang of IFN function through its role in modulating crosstalk between multiple cytokines by both feedforward and feedback regulation of common signaling intermediates and postulate a homeostatic role for IFN through tonic signaling in the absence of acute infection. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22365663      PMCID: PMC3294371          DOI: 10.1016/j.immuni.2012.01.011

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  100 in total

Review 1.  Paradoxical roles of the immune system during cancer development.

Authors:  Karin E de Visser; Alexandra Eichten; Lisa M Coussens
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

2.  Type I IFN contributes to NK cell homeostasis, activation, and antitumor function.

Authors:  Jeremy B Swann; Yoshihiro Hayakawa; Nadeen Zerafa; Kathleen C F Sheehan; Bernadette Scott; Robert D Schreiber; Paul Hertzog; Mark J Smyth
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

3.  Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide.

Authors:  Karen E Thomas; Carole L Galligan; Raj Deonarain Newman; Eleanor N Fish; Stefanie N Vogel
Journal:  J Biol Chem       Date:  2006-08-15       Impact factor: 5.157

4.  Modulation of STAT1 protein levels: a mechanism shaping CD8 T-cell responses in vivo.

Authors:  M Pilar Gil; Rachelle Salomon; Jennifer Louten; Christine A Biron
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

5.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

6.  Genomic view of IFN-alpha response in pre-autoimmune NZB/W and MRL/lpr mice.

Authors:  Q Lu; N Shen; X M Li; S L Chen
Journal:  Genes Immun       Date:  2007-08-30       Impact factor: 2.676

7.  Deficiency of the type I interferon receptor protects mice from experimental lupus.

Authors:  Dina C Nacionales; Kindra M Kelly-Scumpia; Pui Y Lee; Jason S Weinstein; Robert Lyons; Eric Sobel; Minoru Satoh; Westley H Reeves
Journal:  Arthritis Rheum       Date:  2007-11

8.  Genetic control directed toward spontaneous IFN-alpha/IFN-beta responses and downstream IFN-gamma expression influences the pathogenesis of a murine psoriasis-like skin disease.

Authors:  Fuyuko Arakura; Shigeaki Hida; Eri Ichikawa; Chihiro Yajima; Shinsuke Nakajima; Toshiaki Saida; Shinsuke Taki
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

Review 9.  Interferon-beta1b in multiple sclerosis.

Authors:  Mathias Buttmann; Peter Rieckmann
Journal:  Expert Rev Neurother       Date:  2007-03       Impact factor: 4.618

10.  High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells.

Authors:  Takuya Miyagi; M Pilar Gil; Xin Wang; Jennifer Louten; Wen-Ming Chu; Christine A Biron
Journal:  J Exp Med       Date:  2007-09-10       Impact factor: 14.307

View more
  205 in total

1.  Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes.

Authors:  Srilalitha Kuruganti; Shane Miersch; Ashlesha Deshpande; Jeffrey A Speir; Bethany D Harris; Jill M Schriewer; R Mark L Buller; Sachdev S Sidhu; Mark R Walter
Journal:  J Biol Chem       Date:  2015-11-06       Impact factor: 5.157

2.  Single cell RNA sequencing identifies an early monocyte gene signature in acute respiratory distress syndrome.

Authors:  Yale Jiang; Brian R Rosborough; Jie Chen; Sudipta Das; Georgios D Kitsios; Bryan J McVerry; Rama K Mallampalli; Janet S Lee; Anuradha Ray; Wei Chen; Prabir Ray
Journal:  JCI Insight       Date:  2020-07-09

3.  CCR2 Signaling Selectively Regulates IFN-α: Role of β-Arrestin 2 in IFNAR1 Internalization.

Authors:  Dionna W Williams; Lauren C Askew; Elonna Jones; Janice E Clements
Journal:  J Immunol       Date:  2018-11-30       Impact factor: 5.422

4.  Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer.

Authors:  Merit L Goodman; Gloria M Trinca; Katherine R Walter; Evangelia K Papachristou; Clive S D'Santos; Tianbao Li; Qi Liu; Zhao Lai; Prabhakar Chalise; Rashna Madan; Fang Fan; Mary A Markiewicz; Victor X Jin; Jason S Carroll; Christy R Hagan
Journal:  J Immunol       Date:  2019-04-01       Impact factor: 5.422

Review 5.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

6.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

7.  Noncanonical Effects of IRF9 in Intestinal Inflammation: More than Type I and Type III Interferons.

Authors:  Isabella Rauch; Felix Rosebrock; Eva Hainzl; Susanne Heider; Andrea Majoros; Sebastian Wienerroither; Birgit Strobl; Silvia Stockinger; Lukas Kenner; Mathias Müller; Thomas Decker
Journal:  Mol Cell Biol       Date:  2015-04-27       Impact factor: 4.272

8.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

9.  Cutting Edge: Direct Sensing of TLR7 Ligands and Type I IFN by the Common Myeloid Progenitor Promotes mTOR/PI3K-Dependent Emergency Myelopoiesis.

Authors:  Matthew B Buechler; Holly M Akilesh; Jessica A Hamerman
Journal:  J Immunol       Date:  2016-08-26       Impact factor: 5.422

10.  Commensal Microbiota Modulation of Natural Resistance to Virus Infection.

Authors:  Kailyn L Stefan; Myoungjoo V Kim; Akiko Iwasaki; Dennis L Kasper
Journal:  Cell       Date:  2020-11-18       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.